TIMIStudyGroup (Twitter) - ユーザ詳細

TIMI Study Group (@TIMIStudyGroup)

投稿
お気に入り
フォロー
フォロワー

投稿一覧（最新100件）

7 0 0 0 OA Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―

Good news for Asian pts with ASCVD: New data from #FOURIER shows adding #PCSK9 inhibitor #evolocumab to statin robustly lowers LDL-C and is as equally safe & efficacious to prevent CV events in Asians as in non-Asians. @KazumaOyama @rgiugliano https://t.co/yhXdZszbwW

5 0 0 0 OA The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-

Read Eri Toda Kato and Shinya Goto's review in the Journal of Atherosclerosis and Thrombosis on TIMI Study Group's contribution to the advancement of cardiology. https://t.co/4274nl0Uas

TIMI Study Group (@TIMIStudyGroup)

投稿一覧（最新100件）

7 0 0 0 OA Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―

5 0 0 0 OA The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-

お気に入り一覧（最新100件）

フォロー（325ユーザ）の投稿一覧（直近7日間）

フォロワー（4072ユーザ）の投稿一覧（直近7日間）